Registered title, quoted from ClinicalTrials.gov
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Union Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07429721, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
12. Men and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent until 1 year after the use of the study drug;
Inclusion criterion 26
13. Men and women of childbearing potential must agree not to donate sperm or eggs (oocytes) or other reproductive cells from the time of signing the informed consent until 1 year after the use of the study drug;
Inclusion criterion 27
Received targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive research medical devices within 5 half-lives;
Exclusion criterion 2
Received immune/non-immune-directed systemic therapy within 1 week;
Exclusion criterion 3
Received cytotoxic therapy within 2 weeks;
Exclusion criterion 4
Received proteasome inhibitors within 2 weeks;
Exclusion criterion 5
Received immunomodulatory therapy within 1 week.
Exclusion criterion 6
Received radiotherapy within 4 weeks (if the radiotherapy covered ≤5% of bone marrow reserve, the subject is eligible regardless of the radiotherapy end date);
Exclusion criterion 7
2. Received allogeneic hematopoietic stem cell transplantation within 6 months or autologous hematopoietic stem cell transplantation within 3 months before infusion;
Exclusion criterion 8
4. Received any treatment using vesicular stomatitis virus G (VSVG) pseudotyped virus;
Exclusion criterion 10
5. ECOG performance status 0-2, with an expected survival of ≥ 3 months;
Inclusion criterion 8
Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin allowed; for patients meeting the ≥ 6 g/dL hemoglobin requirement at screening, red blood cell transfusions are allowed to maintain hemoglobin ≥ 6 g/dL;
Inclusion criterion 10
Absolute neutrophil count (ANC) ≥ 600/μL (no use of granulocyte colony-stimulating factor (G-CSF) within 1 week before screening or pegylated G-CSF within 2 weeks before screening);
Inclusion criterion 11
Platelet count ≥ 50,000/μL;
Inclusion criterion 12
7. Normal renal function: Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥45 mL/min;
Inclusion criterion 14
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0× the upper limit of normal (ULN);
Inclusion criterion 16
Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) ≤2.0× ULN (except for congenital hyperbilirubinemia, e.g., Gilbert's syndrome, direct bilirubin ≤1.5× ULN);
Inclusion criterion 17
4. Disease must be measurable at screening, meeting one or more of the following criteria:
Inclusion criterion 4
3. Had malignancies other than MM before screening, except for: malignancies treated with curative intent, with no known active disease ≥2 years prior to enrollment; or adequately treated non-melanoma skin cancer with no evidence of disease currently;
Exclusion criterion 9
6. Within 6 months before infusion, tested positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA levels above the normal range; tested positive for hepatitis C virus (HCV) antibody with peripheral blood HCV RNA levels above the normal range; tested positive for human immunodeficiency virus (HIV) antibody; or tested positive for syphilis;
Exclusion criterion 12
11. Women of childbearing potential must have a negative pregnancy test at screening and before drug infusion and must not be breastfeeding.
Inclusion criterion 25
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07429721, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1. Age ≥ 18 years, any gender;
- 2. Diagnosed with multiple myeloma (MM) according to IMWG diagnostic criteria;
- 3. Have received at least 2 lines of anti-MM treatment, with at least one full treatment cycle per line, and experienced disease progression during the most recent anti-myeloma treatment or within 12 months after it, confirmed by available clinical evidence; or deemed by the investigator to be refractory to both immunomodulatory agents and proteasome inhibitors, with disease progression during the most recent anti-myeloma treatment or within 2 months after it (according to IMWG diagnostic criteria);
- 4. Disease must be measurable at screening, meeting one or more of the following criteria:
- Serum M protein level ≥ 0.5 g/dL;
- Or urine M protein level ≥ 200 mg/24h;
- Or involved serum free light chain ≥ 10 mg/dL with abnormal serum free light chain κ/λ ratio;
- 5. ECOG performance status 0-2, with an expected survival of ≥ 3 months;
- 6. Bone marrow function test results (from screening or within 2 months prior) meet the following requirements:
- Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin allowed; for patients meeting the ≥ 6 g/dL hemoglobin requirement at screening, red blood cell transfusions are allowed to maintain hemoglobin ≥ 6 g/dL;
- Absolute neutrophil count (ANC) ≥ 600/μL (no use of granulocyte colony-stimulating factor (G-CSF) within 1 week before screening or pegylated G-CSF within 2 weeks before screening);
- Platelet count ≥ 50,000/μL;
- Lymphocyte count ≥ 500/μL;
- 7. Normal renal function: Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥45 mL/min;
- 8. Liver function must meet the following criteria:
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0× the upper limit of normal (ULN);
- Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) ≤2.0× ULN (except for congenital hyperbilirubinemia, e.g., Gilbert's syndrome, direct bilirubin ≤1.5× ULN);
- Albumin ≥3 g/dL;
- 9. Cardiac function must meet the following criteria:
- Left ventricular ejection fraction ≥50% (by echocardiography or MUGA scan);
- No clinically significant pericardial effusion;
- No clinically significant electrocardiogram abnormalities;
- 10. Pulmonary function must meet the following criteria:
- Blood oxygen saturation ≥90% without oxygen supplementation;
- 11. Women of childbearing potential must have a negative pregnancy test at screening and before drug infusion and must not be breastfeeding.
- 12. Men and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent until 1 year after the use of the study drug;
- 13. Men and women of childbearing potential must agree not to donate sperm or eggs (oocytes) or other reproductive cells from the time of signing the informed consent until 1 year after the use of the study drug;
- 14. The subject or their legal guardian agrees to participate in this clinical trial and signs the informed consent form (ICF), indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the study.
Exclusion Criteria:
- 1.During screening, participants who have received other anticancer treatments (based mainly on investigator judgment):
- Received targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive research medical devices within 5 half-lives;
- Received immune/non-immune-directed systemic therapy within 1 week;
- Received cytotoxic therapy within 2 weeks;
- Received proteasome inhibitors within 2 weeks;
- Received immunomodulatory therapy within 1 week.
- Received radiotherapy within 4 weeks (if the radiotherapy covered ≤5% of bone marrow reserve, the subject is eligible regardless of the radiotherapy end date);
- 2. Received allogeneic hematopoietic stem cell transplantation within 6 months or autologous hematopoietic stem cell transplantation within 3 months before infusion;
- 3. Had malignancies other than MM before screening, except for: malignancies treated with curative intent, with no known active disease ≥2 years prior to enrollment; or adequately treated non-melanoma skin cancer with no evidence of disease currently;
- 4. Received any treatment using vesicular stomatitis virus G (VSVG) pseudotyped virus;
- 5. Had severe, uncontrolled infection symptoms (bacterial, viral, fungal, etc.) during the screening period;
- 6. Within 6 months before infusion, tested positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA levels above the normal range; tested positive for hepatitis C virus (HCV) antibody with peripheral blood HCV RNA levels above the normal range; tested positive for human immunodeficiency virus (HIV) antibody; or tested positive for syphilis;
- 7. Had symptomatic heart failure or other serious cardiac diseases such as severe arrhythmias:
- New York Heart Association (NYHA) class III or IV congestive heart failure;
- Experienced myocardial infarction or underwent coronary artery bypass graft (CABG) or coronary stent implantation within 6 months prior to signing the ICF;
- Had clinically significant ventricular arrhythmias, or a history of unexplained syncope (excluding cases caused by vasovagal response or dehydration);
- Had a history of severe non-ischemic cardiomyopathy;
- 8. Other clinically significant diseases, including:
- Primary immunodeficiency;
- Stroke or seizure within 6 months prior to screening;
- Clear clinical evidence of dementia or altered mental status;
- Parkinson's disease or Parkinsonian movement disorders or history thereof;
- 9. Undergoing surgery within 2 weeks of administration or planned surgery within 2 weeks after administration, except for surgeries under local anesthesia;
- 10. Administration of live attenuated vaccines within 1 month before dosing;
- 11. Known severe allergic reaction to QI-019B or any of its formulation components;
- 12. Known severe allergic reaction to tocilizumab;
- 13. Unsuitable for establishing intravenous access;
- 14. Other conditions deemed by the investigator to be unsuitable for participation in this study.
Quoted from ClinicalTrials.gov, NCT07429721, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07429721, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.